Skip to main content

Drug Interactions between HDL Benefit and telbivudine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

niacin telbivudine

Applies to: HDL Benefit (niacin) and telbivudine

MONITOR: Prolonged use of certain nucleoside reverse transcriptase inhibitors may commonly cause myopathy, including rare cases of rhabdomyolysis. It is not known if the risk of myopathy is increased during concurrent administration of other agents associated with myopathy, including corticosteroids, fibric acid derivatives, HMG-CoA reductase inhibitors, chloroquine, hydroxychloroquine, penicillamine, and lipid-lowering doses of niacin.

MANAGEMENT: Clinicians should carefully consider the benefits versus risks prior to prescribing these agents together. Patients should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be interrupted if myopathy is suspected, and discontinued if myopathy is diagnosed.

References (2)
  1. (2001) "Product Information. Retrovir (zidovudine)." Glaxo Wellcome
  2. (2006) "Product Information. Tyzeka (telbivudine)." IDEC Pharmaceuticals Corporation

Drug and food interactions

Moderate

niacin food

Applies to: HDL Benefit (niacin)

GENERALLY AVOID: Ethanol can exacerbate the cutaneous flushing that is a common side effect of niacin. At least one case of delirium and lactic acidosis has been reported with coadministration of these drugs, although data are limited.

MANAGEMENT: Coadministration should probably be discouraged, particularly since chronic consumption of large amounts of alcohol is associated with hyperlipidemia.

References (1)
  1. Schwab RA, Bachhuber BH (1991) "Delirium and lactic acidosis caused by ethanol and niacin coingestion." Am J Emerg Med, 9, p. 363-5
Minor

niacin food

Applies to: HDL Benefit (niacin)

A single case has been reported in which cutaneous flushing and tremors were noted in a woman who was taking niacin while wearing a nicotine patch. The mechanism is suspected to be synergistic cutaneous vasodilatory effects. The clinical significance of this possible interaction is not known.

References (1)
  1. Rockwell KA Jr (1993) "Potential interaction between niacin and transdermal nicotine." Ann Pharmacother, 27, p. 1283-8

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer